KAZAN, Russian Federation, April 6 /PRNewswire-FirstCall/ - Neuro-Biotech Corp. (Pink Sheets: MRES) (OTCQB) Mr. Rustern Yusupov Vice-President Neuro-Biotech Corp. Is pleased to announce that after discussions between Neuro-Biotech Corp and Credo-TM the company approved the new direction of the company. Mr. Yusupov said that the both Company Boards have approved the immediate implementation of the business plan that has been in development for the past few months. And following the meeting with Auric Pharma Science, the new board has decided not to pursue any longer the unsolicited offer that was made by Auric, since after long discussions both companies were not able to agree on a common direction for Neuro-Biotech.

Mr. Yusupov also said that a third party has been identified  to produce the test kit, also two laboratories that met Neuro-Biotech's tests standards that  have the qualified technical personnel. Neuro-Biotech will be providing the required laboratory technician to train the personnel in implementing Neuro-biotech's testing procedures.
Also Mr. Yusupov added that on March 28th, during the Quebec/Russia Innovations Forum which was held in Montreal Technoparc Neuro-Biotech's representative made a presentation to the deputy minister of Ministry of Economical Development of Russian Federation, since Bio-technology field is a major interest for the Russian government and Neuro-Biotech's has developed a very unique and innovative products which is ready to market. This makes Neuro-Biotech to qualify for major private and Russian government funding and grants.

"Every one at Neuro-Biotech is anxious to start producing our products Now that all elements are in place and our product is in great demand as it assists the medical field to provide easy and fast diagnostic treatment to their patient, this will also help private and public institutions to save millions of dollars in unnecessary expenses."  Stated Mr. Yusupov.

Forward Looking Statements  

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.